An interventional study of participation of the general practitioner in Cervical Cancer, sponsored by Centre Hospitalier Intercommunal Creteil. Recruiting at 1 site in France. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Centre Hospitalier Intercommunal Creteil · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Uterine Cervical Neoplasms with a site in France — 31 open to participants now, 46 under way, 5 of them phase 3. Uterine Cervical Neoplasms · France.
Among the 147 studies in Uterine Cervical Neoplasms with a site in France, this one is the 4th largest by planned enrollment of the 117 interventional ones that give a count, is one of 4 that started in 2026, is one of 45 with no phase, reaches primary completion later than 22 of the 45 other live ones, and was the 121st registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →31 of the 147 studies in Uterine Cervical Neoplasms with a site in France are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in France, United States, Argentina and 26 more countries
Ages 18+ · Women only
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+ · Women only
Centre Paul Strauss · Sites in France
Ages 18+ · Women only
Institut Claudius Regaud · Sites in France
Ages 18+
International Agency for Research on Cancer · Sites in France
Ages 30–65 · Women only · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 36 · Phase 3 14 · Phase 4 1
First in 1996; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 11,200 is above the median of 100 across 1,740 interventional studies indexed under Uterine Cervical Neoplasms.
Median enrollment 210 across the 117 interventional studies, 174 across the 30 observational. Of the 92 that completed or were terminated, 15 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 147 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Intercommunal Creteil is the lead sponsor of 132 studies on the registry; 37 are open to participants now.
Centre Hospitalier Intercommunal Creteil has 1 study filed under Uterine Cervical Neoplasms — fewer than ten, so there is no comparison to draw.
12 of the studies in Uterine Cervical Neoplasms with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06392997ZIWIGEvaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology | 2026-12 |
| NCT06533059Alterome Therapeutics, Inc.A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | 2026-12-29 |
| NCT05527184AbbVieFirst in Human Study of IMGN151 in Recurrent Gynaecological Cancers | 2027-02 |
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT06923761Grey Wolf TherapeuticsEMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1) | 2027-04-30 |
Add all 12 to your calendar (.ics) → With an account.
Among the 147 studies in Uterine Cervical Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In France, cervical cancer is the 12th most common female cancer with nearly 3,000 new cases per year.
Since 2018, a national Organized Cervical Cancer Screening program (DOCCU) has been set up and concerns all asymptomatic women aged 25 to 65.
This program, managed by the Regional Cancer Screening Coordination Centers (CRCDC), invites women who have not taken a sample within the recommended time frame to consult for screening. However, only 59% of patients participated.
The intervention of the general practitioner, an essential player in prevention, could allow for better awareness.
The objective of the INDIGO study is to evaluate the effectiveness of the intervention of a general practitioner on the participation rate in the DOCCU of patients who are not up to date with their screening.
This is a cluster-randomized trial. Randomization will be performed at the GP practice level to limit the potential contamination bias between doctors within the same practice. GP practices will be randomized either to the 'usual practice' arm or the 'intervention' arm."
If they are in the "intervention" group, they or one of the professionals in their team will contact the patient (phone call, SMS, email, etc.), to encourage her to make an appointment to carry out the screening. Contact arrangements are left to the discretion of each general practitioner..
If they are in the "Usual practice" group, they will use their usual practices to encourage screening.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
the doctor will use their usual practices to encourage screening.
the general practitioner or one of the professionals on their team will contact the patient (phone call, SMS, email, etc.), to encourage them to make an appointment to carry out the screening
Other: participation of the general practitioner
participation of the general practitioner in encouraging cervical cancer screening
screening participation rate
percentage of patients who had a screening Cervical Sample (cytology or HPV test within a timeframe satisfying the HAS recommendations according to age) among patients eligible for screening aged 25 to 65 years
Time frame: 12 month
Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.
Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 19 months is below that.
Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Intercommunal Creteil →